LIPID APP

LIPID APP was conceived as a device aimed at helping the doctor in defining the patient's cardiovascular risk level and in making the most appropriate therapeutic choice.

LIPID APP allows you to define the risk of cardiovascular events calculated using the SCORE-2 (Systematic Coronary Risk Evaluation) risk cards or derived from the presence of high or very high risk conditions (for example those who already have a known cardiovascular disease, type 2 or type 1 diabetes with target organ damage, moderate or severe chronic renal failure), or those who have a single very high risk factor.

LIPID APP also provides information on the LDL cholesterol target recommended by the Guidelines in relation to the risk level and on the distance of the patient's LDL cholesterol level from the target recommended by the Guidelines.

The new version of the LIPID APP, compared to the previous one, offers additional functions, such as the possibility of indicating whether the patient has intolerance to statins or ezetimibe, and to select any lipid-lowering therapies already underway in order to propose a global therapeutic solution.

LIPID APP, in fact, proposes therapeutic options - limited to therapies with statins, ezetimibe and bempedoic acid - with the greatest probability of reducing LDL cholesterol levels sufficiently to reach the recommended target, giving priority to maximum tolerability. In particular, therapeutic solutions that involve the use of low doses of statin in monotherapy or in combination therapy are preferred."

LIPID APP does not in any way replace the judgment of the doctor who is responsible for evaluating the adequacy of what is highlighted by the app in relation to the clinical context.

The information presented in the LIPID APP was derived from the 2019 ESC/EAS guidelines for the management of dyslipidemia.